Historical Valuation
Traws Pharma Inc (TRAW) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of -12.79. The fair price of Traws Pharma Inc (TRAW) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 1.41 USD , Traws Pharma Inc is Undervalued By Fair.
Relative Value
Fair Zone
+Inf-+Inf
Current Price：1.41
Fair
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Traws Pharma Inc (TRAW) has a current Price-to-Book (P/B) ratio of 2.09. Compared to its 3-year average P/B ratio of 0.06 , the current P/B ratio is approximately 3557.19% higher. Relative to its 5-year average P/B ratio of 1.95, the current P/B ratio is about 7.23% higher. Traws Pharma Inc (TRAW) has a Forward Free Cash Flow (FCF) yield of approximately -183.17%. Compared to its 3-year average FCF yield of -164.89%, the current FCF yield is approximately 11.09% lower. Relative to its 5-year average FCF yield of -117.63% , the current FCF yield is about 55.71% lower.
P/B
Median3y
0.06
Median5y
1.95
FCF Yield
Median3y
-164.89
Median5y
-117.63
Competitors Valuation Multiple
AI Analysis for TRAW
The average P/S ratio for TRAW competitors is 2.83, providing a benchmark for relative valuation. Traws Pharma Inc Corp (TRAW.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of -100.00%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for TRAW
1Y
3Y
5Y
Market capitalization of TRAW increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of TRAW in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is TRAW currently overvalued or undervalued?
Traws Pharma Inc (TRAW) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of -12.79. The fair price of Traws Pharma Inc (TRAW) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 1.41 USD , Traws Pharma Inc is Undervalued By Fair .
What is Traws Pharma Inc (TRAW) fair value?
TRAW's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Traws Pharma Inc (TRAW) is between +Inf to +Inf according to relative valuation methord.
How does TRAW's valuation metrics compare to the industry average?
The average P/S ratio for TRAW's competitors is 2.83, providing a benchmark for relative valuation. Traws Pharma Inc Corp (TRAW) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of -100.00%, this premium appears unsustainable.
What is the current P/B ratio for Traws Pharma Inc (TRAW) as of Jan 09 2026?
As of Jan 09 2026, Traws Pharma Inc (TRAW) has a P/B ratio of 2.09. This indicates that the market values TRAW at 2.09 times its book value.
What is the current FCF Yield for Traws Pharma Inc (TRAW) as of Jan 09 2026?
As of Jan 09 2026, Traws Pharma Inc (TRAW) has a FCF Yield of -183.17%. This means that for every dollar of Traws Pharma Inc’s market capitalization, the company generates -183.17 cents in free cash flow.
What is the current Forward P/E ratio for Traws Pharma Inc (TRAW) as of Jan 09 2026?
As of Jan 09 2026, Traws Pharma Inc (TRAW) has a Forward P/E ratio of -0.77. This means the market is willing to pay $-0.77 for every dollar of Traws Pharma Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Traws Pharma Inc (TRAW) as of Jan 09 2026?
As of Jan 09 2026, Traws Pharma Inc (TRAW) has a Forward P/S ratio of 0.00. This means the market is valuing TRAW at $0.00 for every dollar of expected revenue over the next 12 months.